XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Tables)
 6 Months Ended
Jun. 30, 2020
Schedule of ownership percentages of investee
  Ownership percentage    
   June 30,   December 31,   Accounting
Name of related party  2020   2019   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.72%   0.72%  Cost Method
BioHopeKing Corporation   6.85%   7.13%  Cost Method
BioFirst Corporation   15.89%   15.89%  Equity Method
Rgene Corporation   31.61%   31.61%  Equity Method
Schedule of extent the investee relies
Name of related party   The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from the investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs
Schedule of long-term investment
   June 30,
2020		   December 31,
2019		 
Non-marketable Cost Method Investments, net  (Unaudited)     
Braingenesis Biotechnology Co., Ltd.  $7,500   $7,367 
Genepharm Biotech Corporation   22,897    22,493 
BioHopeKing Corporation   989,599    1,998,310 
Sub total   1,019,996    2,028,170 
Equity Method Investments, net          
BioFirst Corporation   1,176,605    1,336,449 
Rgene Corporation   -    - 
Total  $2,196,601   $3,364,619 
Schedule of equity investments
   Six Months Ended
June 30,		 
   2020   2019 
   (Unaudited) 
Share of equity method investee losses  $(180,067)  $(117,424)
BioFirst [Member]  
Schedule of balance sheets
   June 30,
 2020		   December 31,
2019		 
   (Unaudited)     
Current Assets  $1,094,018   $1,350,701 
Noncurrent Assets   7,327,261    7,450,032 
Current Liabilities   2,042,882    2,060,460 
Noncurrent Liabilities   103,058    78,888 
Shareholders' Equity   6,275,339    6,661,385 
Schedule of statements of operation
   Six Months Ended
June 30,		 
   2020   2019 
   (Unaudited) 
Net sales  $25,730   $20,446 
Gross profit   3,261    4,214 
Net loss   (832,818)   (543,582)
Share of losses from investments accounted for using the equity method   (180,067)   (117,424)
Rgene [Member]  
Schedule of balance sheets
   June 30,
2020		   December 31,
2019		 
   (Unaudited)     
Current Assets  $81,705   $82,254 
Noncurrent Assets   244,821    62,768 
Current Liabilities   881,742    312,950 
Noncurrent Liabilities   55,450    - 
Shareholders' Deficit   (610,666)   (167,928)
Schedule of statements of operation
   Six Months Ended
June 30,		 
   2020   2019 
   (Unaudited) 
Net sales  $2,237   $- 
Gross Profit   (331,565)   - 
Net loss   (391,686)   (49,896)
Share of loss from investments accounted for using the equity method   -    -